OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

12 Aug 2014
Price Change (% chg)

$-0.15 (-0.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for OMED.OQ


OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential... (more)


Beta: --
Market Cap (Mil.): $565.75
Shares Outstanding (Mil.): 29.76
Dividend: --
Yield (%): --


  OMED.OQ Industry Sector
P/E (TTM): 3.17 146.95 33.57
EPS (TTM): 6.00 -- --
ROI: -20.80 -3.15 18.05
ROE: -- -7.10 18.79
Search Stocks

OncoMed halts enrollment in trials of two cancer drugs

- OncoMed Pharmaceuticals Inc said it halted patient enrollment and dosing in all ongoing early-stage trials of two of its experimental cancer drugs over concerns of bone damage.

13 Jun 2014


  Price Change
Amgen, Inc. (AMGN.OQ) $132.99 -0.23
Astellas Pharma Inc (4503.T) ¥1,496 -1.00
AstraZeneca plc (AZN.L) 4,238.50p +21.50
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $91.43 +0.12
Roche Holding Ltd. (ROG.VX) CHF266.30 +0.90
GlaxoSmithKline plc (GSK.L) 1,412.50p +9.50
Johnson & Johnson (JNJ.N) $102.96 +0.26
Eli Lilly and Co (LLY.N) $62.16 +0.81

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
Provider: Zacks Investment Research Inc.
Provider: Zacks Investment Research Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks